UnknownPhase 2NCT06255847

Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanxi Bethune Hospital
Principal Investigator
Xiaomin Zhang
Shanxi Bethune Hospital
Intervention
Pomalidomide, cyclophosphamide combined with dexametha(drug)
Enrollment
43 target
Eligibility
18 years · All sexes
Timeline
20222025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06255847 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials